These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 10083505)

  • 1. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
    Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA; Bakran A; Brown MW; Grinyo J; Hammad A; Hyatt D; Owens G
    Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
    [No Abstract]   [Full Text] [Related]  

  • 4. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
    Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
    Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

  • 6. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycophenolate mofetil in living donor renal allograft recipients.
    Park K; Moon JI; Kim SI; Kim YS
    Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
    [No Abstract]   [Full Text] [Related]  

  • 8. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
    Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 13. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
    Weber M; Deng S; Arenas J; Aradhye S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
    Transplant Proc; 1997 Dec; 29(8):3669-70. PubMed ID: 9414883
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
    Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
    Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function.
    Liu B; Lin ZB; Ming CS; Zhang WJ; Chen ZS; Sha B; Zeng FJ; Chen S
    Transplant Proc; 2003 Feb; 35(1):87-8. PubMed ID: 12591319
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish Group. Spanish Group of the CellCept Study.
    Puig i Marí JM
    Transplant Proc; 1999 Sep; 31(6):2256-8. PubMed ID: 10500566
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients.
    Suhail SM; Vathsala A; Lou HX; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy of mycophenolate mofetil treatment in the prevention of acute renal rejection is related to plasma level of mycophenolic acid.
    Kuriata-Kordek M; Boratyńska M; Klinger M; Woźniak M; Urbaniak J; Szyber P; Patrzalek D; Tupka D
    Transplant Proc; 2002 Nov; 34(7):2985-7. PubMed ID: 12431678
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised open clinical trial of conversion from mycophenolate mofetil to azathioprine in cadaveric renal transplantation.
    Nowacka-Cieciura E; Kamiñska B; Cieciura T; Gradowska L; Pazik J; Lao M; Rowiñski W; Paczek L
    Transpl Int; 2000; 13 Suppl 1():S68-72. PubMed ID: 11111965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.